RE:RE:RE:RE:Wow!Trussel09,
You make some good points there. However, it is hard to predict how turbulent history will affect the share price. Will start of Phase 3 lead to putting the turbulent ASSURE trial behind us or not? If not, then you are probably right that we may be in for a small bounce and a long wait until other exciting news comes along. However, if the past is forgiven and the focus in on the future potential of a blockbuster drug, then we may be surprised in a good way. New analyst reports are forthcoming, hopefully leading to more public exposure. The official trial announcement on ClinicalTrials.gov next week on October 21 that same day will hopefully lead to more information about the trial being available and enrollment should kick off anytime thereafter. And Resverlogix's presentation at the BIO Investor Forum in San Francisco on October 21 may just be old news but could also be a venue for something new.
On the science end, looks like there's the potential for some great science exposure for Resverlogix and Zenith for their cardiovascular, nephrology and oncology programs. There are
3 meetings that are happening in the first 2 weeks of November (American Heart, ASN Kidney Week, AACR) that Resverlogix and Zenith may be presenting at. The only one I can find a presentation listed for sure is the American Heart conference, but Zenith is attending AACR and the Resverlogix AGM transcript alluded to Dr. Kalanta presenting soon at a Nephrology meeting in San Diego. Don't underestimate the value of science exposure now that we are heading into Phase 3. Maybe it will have no effect, but you can't predict how the market will react.
Also, there is the CETP wildcard. The call by the ACCELERATE data monitoring committee to end the Phase 3 trial of evacetrapid seems to have placed the final nail in the coffin for CETP inhibitors. Merck's anacetrapib is still in its Phase 3 REVEAL study, but just read the stories this week and it sounds like cardiologist have already closed the door on anacetrapib. Merck has said that the steering committee estimates that the first interim analysis will take place towards the end of this year. What would it mean if REVEAL was also ended? That would mean that really the only other drug to raise HDL would be done for. This could finally be the chance for RVX-208 to shake the CETP inhibitor baggage and shine as the next likely cardiovascular therapy in Phase 3 trials to treat low-HDL patients.
I'm just offering these as potential, but surely not guaranteed, influences on the near term share price. Like you said, it could a a long wait. Will we see a bounce? How much of a bounce? Will the dust settle or will other news/exposure lead to a continued upswing? Will the trend for shareprice to decrease on good news continue? Who knows. Play the swings if you want to but I'll stay long and strong. Personal preference. It sure takes guts to play the swings, but you seem to be quite good at it so good for you.
Best regards,
BearDownAZ